Full Text Full Text (PDF) Supplemental table Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Alessi-Severini, S. Articles by Enns, M. W. Search for Related Content PubMed Citation Articles by Alessi-Severini, S. Articles by Enns, M. W. Costs, Cost Analysis Service Utilization Atypical Neuroleptics Conventional Neuroleptics Schizophrenia Spectrum Disorders Related Article

Utilization and Costs of Antipsychotic Agents: A Canadian Population-Based Study, 1996–2006

OBJECTIVE: This study evaluated the prescribing patterns and costs for antipsychotic agents in the population of the Canadian province of Manitoba over the past decade. METHODS: A population-based study of antipsychotic utilization and costs was conducted on data collected from the administrative databases of the Manitoba Population Health Data Repository and the Statistics Canada census between index years 1996 and 2006 (April 1, 1995, through March 31, 2006). RESULTS: The total annual number of antipsychotic prescriptions dispensed in Manitoba increased by 227% between 1996 and 2006, and the prevalence of antipsychotic users increased by 62% over the same time interval. The fastest-growing segment of antipsychotic users in Manitoba appears to be young males, who increased from .16% in 1996 to .88% in 2006. The highest numbers of prescriptions were reported for schizophrenia, dementia, and conduct disorder. Annual expenditures for antipsychotics increased from $1.7 million in 1996 to $22.0 million in 2006 (expenditures are in Canadian dollars). The cost of second-generation agents reached 80% of total antipsychotic expenditures in 2006; risperidone was the most prescribed agent in all age groups of patients. The per-patient annual cost of antipsychotic pharmacotherapy increased by approximately 680% between 1996 and 2006 in Manitoba. CONCLUSIONS: The number of antipsychotic prescriptions and the prevalence of users of antipsychotic medications increased significantly in Manitoba over the study period, despite a steady-state population of approximately 1.2 million. Incremental costs relative to the use of antipsychotic medications can be explained by the market penetration of the second-generation agents and their expanded use in the treatment of various diagnoses.

Related Article:

May 2008: This Month's Highlights
Psychiatr Serv 2008 59: 475. [Full Text] [PDF]

This article has been cited by other articles:

				J. Moncrieff Changing the balance of psychosis treatment: INVITED COMMENTARY ON ... MINIMAL-MEDICATION APPROACHES TO TREATING SCHIZOPHRENIA Advan. Psychiatr. Treat., May 1, 2009; 15(3): 221 - 223. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2008 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us